Last-Chance access: experimental eye treatment opens for 75 RP patients

NCT ID NCT06574997

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This program offers an experimental treatment called OCU400 to up to 75 adults with retinitis pigmentosa (RP) who cannot join the main Phase 3 study. Participants must be 18 or older, have a confirmed genetic diagnosis of RP (except a specific mutation), and have remaining light-sensing cells in the eye. The goal is to provide access when no approved alternative is available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Advanced Research

    Deerfield Beach, Florida, 33064, United States

  • Associated Retina Consultants

    Phoenix, Arizona, 85020, United States

  • Erie Retina Research

    Erie, Pennsylvania, 16507, United States

  • Gundersen Health

    La Crosse, Wisconsin, 54601, United States